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Abstract
Human African trypanosomiasis (HAT, sleeping sickness) ranks among the most neglected
tropical diseases based on limited availability of drugs that are safe and efficacious, particu-
larly against the second stage (central nervous system [CNS]) of infection. In response to
this largely unmet need for new treatments, the Consortium for Parasitic Drug Development
developed novel parenteral diamidines and corresponding oral prodrugs that have shown
cure of a murine model of second stage HAT. As a rationale for selection of one of these
compounds for further development, the pharmacokinetics and efficacy of intramuscular
(IM) active diamidine 2,5-bis(5-amidino-2-pyridyl)furan (DB829; CPD-0802) and oral pro-
drug2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868) were compared in the vervet
monkey model of second stage HAT. Treatment was initiated 28 days post-infection of mon-
keys with T. b. rhodesiense KETRI 2537. Results showed that IM DB829 at 5 mg/kg/day for
5 consecutive days, 5 mg/kg/day every other day for 5 doses, or 2.5 mg/kg/day for 5 conse-
cutive days cured all monkeys (5/5). Oral DB868 was less successful, with no cures (0/2) at
3 mg/kg/day for 10 days and cure rates of 1/4 at 10 mg/kg/day for 10 days and 20 mg/kg/
day for 10 days; in total, only 2/10 monkeys were cured with DB868 dose regimens. The
geometric mean plasma Cmax of IM DB829 at 5 mg/kg following the last of 5 doses was
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25-fold greater than that after 10 daily oral doses of DB868 at 20 mg/kg. These data suggest
that the active diamidine DB829, administered IM, should be considered for further develop-
ment as a potential new treatment for second stage HAT.
Author Summary
Treatment of human African trypanosomiasis (HAT, sleeping sickness) suffers from a
shortage of medicines that are both effective, especially against the second (late) stage of
the disease, and safe for patients. The development of new HAT medicines also has been
significantly influenced by the perceived need for easily administered oral medicines to re-
duce the need for hospitalization of patients in resource-poor settings where HAT typically
occurs. However, the clinical status of second stage patients is likely to dictate the need
for their hospitalization, thus both oral and parenterally administered medicines would
be utilised effectively. Therefore, in an effort to develop new medicines that meet
efficacy and safety requirements, we evaluated a novel injectable diamidine 2,5-bis(5-
amidino-2-pyridyl)furan (DB829; CPD-0802) and its oral prodrug formulation 2,5-bis
[5-(N-methoxyamidino)-2-pyridyl]furan (DB868) in the vervet monkey model of second
stage HAT. Treatment with either compound was initiated 28 days post-infection of mon-
keys with T. b. rhodesiense KETRI 2537. DB829 was dosed at 5 mg/kg/day for 5 consecu-
tive days, 5 mg/kg/day every other day for 5 doses or 2.5 mg/kg/day for 5 consecutive days
intramuscularly (IM) while DB868 was administered at 20, 10 or 3 mg/kg/day for 10 con-
secutive days orally. Clinical and parasitological monitoring was carried out for at least
300 days before the monkeys were declared cured. All IM DB829 and oral DB868 dose reg-
imens were well tolerated. In addition, all monkeys (5/5) treated with IM DB829 were con-
firmed cured. In contrast, oral DB868 cured only 1/4 monkeys at either 10 or 20 mg/kg
and did not cure any monkey when dosed at 3 mg/kg. These results indicate that IM
DB829 is a suitable compound for further development as treatment for second stage
HAT.
Introduction
Diamidinesare widely used in the control of both animal and human infectious diseases.
Diminazeneaceturate, a diamidine primarily utilized in livestock, has demonstrated activity
against Babesia(bovis and bigemina) and a variety of animal-infective trypanosomes. Pentami-
dineis an aliphatic diamidine used in humans to treat first (early, haemolymphatic) stage
human African trypanosomiasis (HAT), leishmaniasis and Pneumocystis jirovecii (carinii)
pneumonia [1–3]. Despite the proven clinical utility of pentamidine as a therapeutic agent for
first stage Trypanosomabrucei (T. b.)gambienseHAT [3] and the synthesis of potentially more
active aromatic diamidines such as furamidine (DB75 (Fig. 1)) [4, 5], no new diamidines have
been approved for use against HAT or other human diseases. Since 2000, however, there has
been renewed research aimed at developing diamidines with 1) satisfactory bioavailability fol-
lowing oral administration, which would allow for more practical treatment in resource poor
settings where HAT is common, and 2) activity against the difficult to treat second stage HAT,
which is characterised by trypanosome invasion of the central nervous system (CNS) [6].
To address these objectives, novel diamidineprodrugs were developed by masking the posi-
tive charges on diamidines with alkoxy moieties [7]. These prodrugs, especially pafuramidine
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(DB289 (Fig. 1)), were shown subsequently to have improved absorptive permeability in a
human intestinal cell line (Caco-2) compared with the corresponding active diamidine, furami-
dine (DB75) [8, 9]. Furthermore, the prodrugs pafuramidine and DB844 (Fig. 1) were fully cu-
rative in murine models of first and second stage HAT after oral administration [10, 11]. In
monkeys, the prodrug pafuramidine was shown to be fully curative against first stage HAT
after oral administration [12], providing additional evidence that the prodrug strategy is effec-
tive in delivering diamidines to the systemic circulation in different animal species. Despite
these successes, cure rates of the prodrugs against second stage HAT in non-human primates
ranged from none (0/3) for pafuramidine [12] to a moderate improvement (3/7) for DB844
[13], suggesting the need to identify oral and/or parenterally administered analogues with im-
proved blood-brain barrier (BBB) permeability. Thus, while these prodrugs satisfied the first
goal, identifying orally active compounds for the treatment of HAT, they did not satisfy
the second goal, identifying compounds with adequate activity against second stage HAT.
The active diamidine 2,5-bis(5-amidino-2-pyridyl)furan (DB829) and its oral prodrug2,5-
bis[5-(N-methoxyamidino)-2-pyridyl]furan (DB868 (Fig. 1)) were shown to be fully curative
in the murine model of second stage HAT (T. b. brucei GVR35) [11], suggesting that at
least DB829 had acceptable activity in this species. Oral DB868 was subsequently shown to be
well-tolerated and fully curative against first stage HAT in monkeys [14]. However, the activity
of DB868 and DB829 in a monkey model of second stage HAT remained undetermined.
Therefore, the aims of the current study were to 1) investigate the efficacy of both DB829 after
intramuscular (IM) administration and DB868 after oral administration in the vervet monkey
model of second stage HAT and 2) compare the pharmacokinetics of DB829 and DB868 in in-
fected vervet monkeys.
Materials and Methods
Ethics
The experimental guidelines and procedures used in this study were approved (Ref: C/TR/4/
325/124) by the Institutional Animal Care and Use Committee at the Trypanosomiasis Re-
search Centre of the Kenya Agricultural Research Institute (TRC-KARI). These IACUC regula-
tions conformed to the “Guidelines for Care and Use of Laboratory Animals in Kenya”
provided by the Kenya Veterinary Association.
Trypanocidal Drugs
DB829, supplied by the Consortium for Parasitic Drug Development (CPDD), was originally
synthesised as described [7]. A hydrochloride salt form was synthesised by Scynexis Inc.
(Research Triangle Park, NC, USA). The diacetate salt form used in this study (CPD-0802; Lot
Fig 1. Structures of active diamidines and corresponding prodrugs.
doi:10.1371/journal.pntd.0003409.g001
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#SP117-ACE-P5; FW = 451.648) was synthesised by Solvias AG (Basel, Switzerland), by first
dissociating the hydrochloride molecule from the Scynexis Inc. compound batch and then
recrystalizing in the presence of acetic acid. The final compound had a chemical purity of
97.2% as determined by nuclear magnetic resonance (NMR) and high performance liquid
chromatography (HPLC). The compound was protected from light at all times. DB829 was re-
constituted in 5% (w/v) dextrose in water to yield 5or 10 mg/mL, and was administered IM to
the monkeys at 0.5 mL/kg body weight. Each dose was administered as two aliquots at separate
sites on the same limb; subsequent doses were administered on alternating limbs. Dosing solu-
tions were prepared daily immediately before dosing.
DB868, also supplied by the CPDD, was originally synthesised as described [7]. The diace-
tate salt form used in this study (CPD-007–10; Lot #2-JXS-28; FW = 564.370) was synthesised
by Scynexis Inc. and had a chemical purity of 95.6% as determined by NMR and HPLC. As
with DB829, DB868 was protected from light at all times. DB868 dosing solutions were pre-
pared daily by reconstituting the drug in distilled de-ionised water to yield1.5, 5, or 10 mg/mL,
and were administered orally to the monkeys at 2 mL/kg body weight. Dosing solutions were
prepared immediately before dosing.
Experimental Animals
Eighteen vervet monkeys [Chlorocebus (Cercopithecus) aethiops; African green monkeys],
weighing between 2.5 and 5.5kg, were used. Following acquisition from the Institute of Primate
Research (Nairobi, Kenya), these monkeys were subjected to routine 90-day quarantine proce-
dures designed to ensure a lack of infectious diseases [15, 16]. The monkeys were housed in
stainless steel cages and maintained on a diet of fresh fruits and vegetables (bananas, tomatoes,
carrots and green maize) and commercial monkey cubes (Unga Feeds, Nakuru, Kenya) fed
twice daily [14]. The commercial monkey cubes were manufactured to have the following nu-
trient composition: crude protein, 19.4% (w/w); crude fiber, 5.6% (w/w); ether extracts that in-
clude fats and lipids, 4.2% (w/w); and nitrogen-free extracts, 66.5% (w/w) [14]. Clean drinking
water was provided ad libitum.
Study Design
The current study used the KETRI vervet monkey model of HAT, a model developed over
30 years ago through the experimental infection of vervet monkeys with T. b. rhodesiense [17].
The resultant infections were found to mimic human sleeping sickness clinically, pathological-
ly, and immunologically [18, 19, 20, 21]. Trypanosomes were identified in peripheral blood
first and cerebrospinal fluid (CSF) second, allowing the disease to be classified into an early
(haemo-lymphatic) and a late (central nervous system [CNS]) stage, similar to the human dis-
ease [18, 19]. This model has been used widely and has been determined to be a reproducible
tool for the study of pathogenesis and product (drugs and diagnostics) evaluation [15, 22, 23].
Monkey trypanosomal infections have been determined to be invariably fatal without thera-
peutic intervention [10], a characteristic also widely accepted as true for human
sleeping sickness.
The efficacies of the active drug DB829 (CPD-0802)administered IM and the prodrug
DB868 administered orally against the KETRI vervet monkey model of second stage HAT were
evaluated in the current study. At the beginning of each experiment, baseline data (weight, clin-
ical and haematological parameters) were collected once every week for 2 weeks, after which
monkeys were infected by intravenous injection of approximately 104 T. b. rhodesiense KETRI
2537 trypanosomes diluted from the infected blood of immunosuppressed donor Swiss white
mice [13–17]. Parasitaemia and CSF parasitosis were monitored using established techniques
Chemotherapy of Second Stage HAT with Novel Diamidines DB829 and DB868
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003409 February 5, 2015 4 / 22
for blood trypanosomes [24, 25] and CSF trypanosomes [13, 26], respectively. Treatment with
DB829 or DB868 was initiated 28 days post-infection (DPI), following confirmation of second
stage HAT using the presence of trypanosomes and elevated white cells (> 5 cells/µL) in CSF
as biomarkers [3].
Due to a regulated freeze on acquisitions of new non-human primates, only six monkeys
were available for the IM DB829 study. These animals were divided into three treatment
groups, each consisting of one male and one female, to compare dose-responsiveness between
consecutive- and alternate-day dosing. Monkeys were treated with 2.5 or 5 mg/kg/day for
5 consecutive days or with 5 mg/kg/day on alternating days for a total of 5 doses (Table 1).
Twelve additional monkeys were available for the oral DB868 efficacy study. These animals
were, before infection, divided into three groups, each consisting of two males and two females.
DB868 was administered orally to each group at 3, 10 or 20 mg/kg/day for 10 consecutive days
(Table 2). However, two monkeys that had been allocated to the 3 mg/kg/day dose-group did
not become blood or CSF trypanosome positive and were consequently withdrawn from the
study, leaving only two monkeys, a male (monkey 687) and a female (monkey 670), in that
group (Table 2).
Parasitaemia post-infection was monitored daily, using ear-prick capillary blood, through
the completion of DB868 and DB829 treatment. Following the last drug dose (LDD), blood
and CSF samples were examined for trypanosomes at 1, 4, 7, and 14 days to determine the end
of treatment (EoT) response; monkeys which were positive for trypanosomes in either blood or
CSF at the end of this 14-day period were classified as treatment failures/not cured while those
that were free of trypanosomes were classified as provisionally cured. After the 14-day EoT
evaluations, parasitaemia examinations were continued twice weekly to 300 days post-LDD
as described previously [12, 13]. Additionally, physical examinations and haematological as-
sessments were carried out once weekly up to 28 days post-LDD, once every two weeks be-
tween 28 and 100 days post-LDD, and monthly thereafter until the end of the study as
described previously [12, 13]. At 300 days post-LDD, monkeys were considered cured if they
remained normal clinically and parasite-free in the blood and CSF. Pharmacokinetic outcomes
were monitored for a minimum of 60 days post-LDD as described previously [13]. To facilitate
the collection of blood and CSF for these assessments, the monkeys were anaesthetised with an
Table 1. Efficacy of intramuscular DB829 against second stage T. b. rhodesiense infection in vervet monkeys.
Parameter/Outcome Intramuscular DB829 (CPD-0802)
5 mg/kg × 5 days 5 mg/kg × 5
alternate days
2.5mg/kg × 5
days
Overall Results
Monkey ID 569F 659M 668M 676F 546M 693F
Prepatent period (DPI) 4 4 5 5 4 3 4 (3–5)a
Peak parasitaemia (Log10 P) 7.2 7.8 7.8 7.5 7.5 8.1 7.7± 0.1
b
Time to parasitization of CSF (days) 27 27 21 21 27 14 24(14–27)a
Peak number of trypanosomes/μL of CSF 1 1 1 1 1 1 1
Trypanosomes at EoT Neg Neg Neg Neg Neg Neg 6/6
Provisional efficacy at 100 days post-LDD of DB829 Cured Cured Cured Cured Cured Cured 6/6
Final efficacy assessment at 300 days post-LDD of DB829 Cured WD (91) Cured Cured Cured Cured 5/5
Cured/treated 1/1 2/2 2/2
Key: DPI, days post-infection; P, parasitaemia; CSF, cerebrospinal fluid; EoT, end of treatment; LDD, last drug dose; F, female; M, male; Neg, Negative;
WD (91), withdrawn 91 days post-LDD; a, median (range); b, mean ± standard error of mean.
doi:10.1371/journal.pntd.0003409.t001
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IM injection of ketamine HCl (10–15 mg/kg) and diazepam (0.5 mg/kg). Monkeys that re-
lapsed, characterized by trypanosome recrudescence in the blood or CSF, were rescue-treated
with melarsoprol. Melarsoprol (Mel B), supplied by the World Health Organization as a 3.6%
(w/v) solution in propylene glycol, was administered intravenously at 3.6 mg/kg/day for 4
consecutive days.
HPLC-MS/MS Quantification of DB868 and DB829 in Monkey Plasma
Plasma samples were processed for quantification of DB868 and DB829 by high performance
liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) as described previously
[14]. CSF samples were processed in a manner similar to that of plasma samples.
Criteria for Euthanasia of Monkeys
The study monkeys that relapsed after treatment were withdrawn from the study and humane-
ly euthanized. The humane endpoints for these animals were determined as described in
“recognition and alleviation of pain in laboratory animals” (http://www.nap.edu/catalog/
12526.html). The key clinical parameters that were monitored and used to aid decision making
on when to euthanize study subjects included a monkey’s inability or reluctance to perch and
consumption of less than 1/4 of normal daily feed intake for 2–3 consecutive days as summa-
rized previously [13, 14, 16]. The affected monkeys were euthanized by intravenous adminis-
tration of 20% (w/v) pentobarbitone sodium solution (150 mg/kg body weight).
Data Analysis
Clinical and haematological data were analysed using Statview for Windows Version 5.0.1
(1995–1998; SAS Institute Inc., Cary, NC, USA). Repeated measures ANOVA, with Fisher’s
PLSD post hoc test, was used to test the effect of trypanosome infection on haematologic pa-
rameters in comparison with respective baseline values (α = 0.05). In addition, the effects of IM
DB829 and oral DB868 on these haematologic parameters in monkeys with confirmed second
stage HAT were tested. Pharmacokinetic outcomes were recovered using traditional non-
Table 2. Efficacy of oral prodrug DB868 against second stage T. b. rhodesiense infection in vervet monkeys.
Parameter/Outcome Oral DB868
20 mg/kg × 10 days 10 mg/kg × 10 days 3 mg/kg × 10 days Overall
Results
Monkey ID 573F 679F 689M 696M 688M 690F 695M 697F 670F 687M
Pre-patent period (DPI) 4 5 5 4 5 5 4 4 7 4 4.5 (3–7)a
Peak parasitaemia (Log10 P) 8.1 7.8 7.8 7.8 7.5 7.8 7.5 7.8 7.2 7.8 7.8 ± 0.1
b
Time to parasitization of CSF (days) 14 27 27 7 21 14 7 7 21 10.5 (7–27)a
Peak number of trypanosomes/μL of CSF 2 1 1 1 1 1 1 1 2 1 (1–2)a
Provisional efficacy at EoT Cured Cured Cured Cured Cured Cured Cured Cured Not
cured
Not
cured
8/10
Provisional efficacy at 100 days post-LDD of
DB868
R Cured Cured Cured R Cured R R 4/10
Final efficacy assessment at 300 days post-
LDD of DB868
R Cured R R R Cured R R 2/10
Cured/treated 1/4 1/4 0/2
Key: DPI, days post-infection; P, parasitaemia; CSF, cerebrospinal fluid; EoT, end of treatment; LDD, last drug dose; F, female; M, male; R, relapsed; a,
median (range); b, mean ± standard error of mean.
doi:10.1371/journal.pntd.0003409.t002
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compartmental methods using Phoenix WinNonlin (version 6.2; Pharsight, Mountain View,
CA, USA).
Results
Parasitaemia, CSF Parasitosis, and Clinical Disease Prior to Treatment
Following intravenous injection of trypanosomes, median (range) pre-patent periods of
4 (3–5) and 4.5 (4–7) days were observed in the DB829and DB868 efficacy studies, respectively
(Tables 1 and 2). Peak parasitaemia reached 107 trypanosomes/mL of blood in individual mon-
keys (Tables 1 and 2), with fluctuations characteristic of trypanosomal infection as demonstrat-
ed by the change in mean parasitaemia (Fig. 2); these observations are similar to primary
parasitaemia data previously reported for this model [13]. Clinically, first stage disease was evi-
dent by transient inappetance, rough haircoats, fluctuating fever, and weight loss (< 5%). Gen-
eral lymphadenopathy and enlargement of the spleen (up to 3-times the pre-infection size) also
were observed.
CSF parasitosis was confirmed in the experimental monkeys at or before the last pre-treat-
ment sampling point at 27 DPI, at a density of 1–2 trypanosomes/μL of CSF (Tables 1 and 2),
confirming that these monkeys had progressed to second stage disease [3]. However, monkey
670F, which did not have detectable trypanosomes in CSF, had elevated CSF white cell num-
bers compared with baseline and was therefore included in the study (Table 2). Two others,
monkeys 646M and 675F, which also were inoculated with trypanosomes with the objective of
Fig 2. Parasitaemia progression in vervet monkeys following infection.Monkeys were infected with T. b. rhodesiense KETRI 2537 on Day 0. Symbols
represent means and standard error of the mean (n = 16).
doi:10.1371/journal.pntd.0003409.g002
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treating them with oral DB868 at 3 mg/kg/day for 10 days, were withdrawn from the study be-
cause they did not become trypanosome positive in blood or CSF and also did not have patho-
logical numbers of CSF white cells. The failure of these two monkeys to become infected may
be due to their participation in a diamidine toxicity study 7 months prior to the start of the cur-
rent study. The response of CSF white cells to infection in the current groups of infected mon-
keys exhibited wide variations between individuals, as shown for three monkeys that were
treated with DB868 (Fig. 3). Clinically, a limited number of monkeys (monkeys 668M, 688M,
689M, and 693F) exhibited signs suggestive of second stage disease, including altered behaviour
and chirping. The monkeys were treated starting at 28 DPI with different dose regimens of
eitherDB829 or DB868 (Tables 1 and 2).
Efficacy of DB829 Dose Regimens
DB829, the active diamidine, was administered IM at 5 mg/kg/day for 5 consecutive days
(monkeys 569F and 659M), 5 mg/kg/day every alternate day for 5 doses (monkeys 668M and
676F), or 2.5 mg/kg/day for 5 consecutive days (monkeys 546M and 693F; Table 1). Monkeys
that were treated with either 5 mg/kg/day dose regimen were blood and CSF parasite negative
1 day post-LDD (Table 3). In contrast, trypanosomes were more persistent in monkeys dosed
with DB829 at 2.5 mg/kg/day; these monkeys were first detected to be negative for trypano-
somes in both blood and CSF at 4 days (monkey 693F) and 7 days (monkey 546M) post-LDD
(Table 3). Subsequently, trypanosomes were undetectable in the blood or CSF of these two
Fig 3. White cell changes in the cerebrospinal fluid of infectedmonkeys treated with the diamidine prodrug DB868.DB868 was administered orally
at 20, 10, or 3 mg/kg/day for 10 days 28–37 days post-infection with T. b. rhodesiense KETRI 2537. M, male.
doi:10.1371/journal.pntd.0003409.g003
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monkeys throughout the remaining EoT evaluation period, contributing to a combined provi-
sional cure rate by DB829 of 6/6. Five out of the six monkeys (monkeys 569F, 668M, 676F,
546M and 693F) remained parasite-free in blood and CSF for more than 300 days post-LDD
(Table 1; Fig. 4) and were declared cured. Monkey 659M (5 mg/kg/day for 5consecutive days)
developed pneumonia and had to be euthanized 91 days post-LDD. Trypanosome recrudes-
cence was not observed in blood or CSF collected from this monkey at any time point post-
treatment. However, since the mandatory post-treatment monitoring period of 300 days was
not completed, the monkey could not be classified as cured and was considered withdrawn
from the study (Table 1). Overall, the final combined cure rate with DB829 treatments was 5/5
(Table 1).
Efficacy of DB868 Dose Regimens
The prodrug DB868 was administered orally to groups of monkeys at 20, 10 and 3mg/kg/day
for 10 consecutive days. The four monkeys dosed with DB868 at 20 mg/kg/day became aparasi-
taemic by the 7th day of treatment at 34 DPI (Fig. 5). CSF trypanosomes were persistent in
some monkeys (monkeys 573F and 696M) but all were cleared 7 days after the LDD (Table 3),
allowing all monkeys to be classified as provisionally cured upon completion of the 14-day EoT
evaluation period (Table 2). However, 3/4 monkeys (monkeys 573F, 689M and 696M)relapsed,
resulting in a final cure rate of 1/4 after the minimum 300 days of post-treatment monitoring
(Table 2). The median (range) time to relapse was 133 (77–161) days post-LDD (Table 3). The
Table 3. Time to clearance of trypanosomes from body fluids of monkeys treated with DB829 or DB868.
Monkey ID Drug (Route) Dose regimen Time to initial clearance of trypanosomes
from body fluids (blood and CSF)
(days post-LDD)
Time to relapse
(days post-LDD)
569F DB829 (IM) 5mg/kg × 5 days, consecutive-day
dosing 28–32 DPI
1 N/A
659M 1 N/A
668M DB829 (IM) 5 mg/kg × 5 days, alternate-day dosing
(28, 30, 30, 32, 34 and 36 DPI)
1 N/A
676F 1 N/A
546M DB829 (IM) 5mg/kg × 5 days, consecutive-day
dosing 28–32 DPI
4 N/A
693F 7 N/A
573F DB868 (Oral) 20 mg/kg × 10 days, 28–37 DPI 7 77
679F 1 N/A
689M 1 161
696M 4 133
688M DB868 (Oral) 10 mg/kg × 10 days, 28–37 DPI 1 56
690F 1 N/A
695M 1 28
697F 1 28
670F DB868 (Oral) 3 mg/kg × 10 days, 28–37 DPI N/A N/A
687M 7 14
Key: F, female; M, male; IM, intramuscular; DPI, days post-infection; CSF, cerebrospinal fluid; LDD, last drug dose;
N/A, not applicable (monkey did not relapse)
doi:10.1371/journal.pntd.0003409.t003
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Fig 4. Resolution of parasitaemia in infected vervet monkeys treated with the active diamidine DB829.
Monkeys were infected with T. b. rhodesiense KETRI 2537 and later confirmed to have progressed to second
stage HAT, were administered with DB829 intramuscularly at (A) 5 mg/kg/day for 5 consecutive days (28–32
days post-infection), (B) 5 mg/kg/day for 5 alternate days (28, 30, 32, 34 and 36 days post-infection), or (C)
2.5 mg/kg/day for 5 consecutive days (28–32 days post-infection). F, female; M, male.
doi:10.1371/journal.pntd.0003409.g004
Chemotherapy of Second Stage HAT with Novel Diamidines DB829 and DB868
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003409 February 5, 2015 10 / 22
Fig 5. Primary and relapse parasitaemia in infected vervet monkeys treated with the diamidine
prodrug DB868. DB868 was administered orally at (A) 20 mg/kg/day, (B) 10 mg/kg/day, or (C) 3 mg/kg/day
for 10 consecutive days following infection with T. b. rhodesiense KETRI 2537 (28–37 days post-infection);
the monkeys were confirmed to have progressed to second stage HAT before initiation of treatment. Relapse
infections occurred at different times in specific individuals. Relapsed monkeys were rescue-treated with
melarsoprol administered intravenously at 3.6 mg/kg/day for 4 consecutive days. F, female; M, male.
doi:10.1371/journal.pntd.0003409.g005
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three relapsed monkeys were confirmed to have CSF trypanosomes, CSF white cell aberrations
(Fig. 3) and/or clinical signs of CNS disease; however, only one (monkey 689M) was diagnosed
to have trypanosomes in the blood (Fig. 5). Clinically, monkey 696M deteriorated quickly, ne-
cessitating euthanasia 130 days post-LDD of DB868. The remaining two relapsed animals
(monkeys 573F and 689M) were successfully rescue-treated with melarsoprol starting at
81 and 168 days post-LDD of DB868, respectively.
All four monkeys that were treated with oral DB868 at 10 mg/kg/day for 10 days responded
in a comparable manner to the higher (20 mg/kg/day) dose group; all became blood parasite
negative by the 7th day of dosing at 34 DPI (Fig. 5) and were negative for trypanosomes in both
blood and CSF at the EoT evaluation (Table 2). In addition, 3/4 monkeys (monkeys 688M,
695M and 697F) relapsed, resulting in a final cure rate of 1/4 (Table 2). However, the median
(range) time to relapse, 28 (28–56) days post-LDD of DB868, was shorter than that of the
higher dose group (Table 3). All three relapsed monkeys (monkeys 688M, 695M and 697F)
were positive for blood trypanosomes (Fig. 5), while only two (monkeys 688M and 697F) had
clinical signs and/or clinico-pathological indicators of CNS disease (Fig. 3). Clinical signs of
CNS involvement in the two monkeys included ataxia, circling and altered behaviour. The
three relapsed monkeys were successfully rescue-treated with melarsoprol starting at either
63 days (monkeys 688M and 697F) or 81 days (monkey 695M) post-LDD of DB868 (100 or
118 DPI, respectively).
The two monkeys treated with DB868 at 3 mg/kg/day for 10 days (monkeys 670F and
687M) (Table 2) also experienced a brief period of aparasitaemia, which started immediately
after the 7th drug dose at 34 DPI (Fig. 5). However, the clinical condition of monkey 670F did
not improve post therapy, necessitating euthanasia 1 day post-LDD of DB868. In monkey
687M, blood trypanosomes reappeared 14 days post-LDD (51 DPI) (Fig. 5; Table 3) while CSF
trypanosomes were not eliminated; taken together, these data indicated that the 3 mg/kg/day
dose regimen did not achieve cure in any monkey (Table 2). The relapse parasitaemia in mon-
key 687M remained near the limit of detection (antilog 5.4 [24]) and tended to be lower in in-
tensity compared to the original parasitaemia in the same monkey (Fig. 5). In contrast, CSF
white cell aberrations were more pronounced in relapse than the period prior to treatment
(Fig. 3). The monkey was rescue-treated with melarsoprol starting at 81 days post-LDD of
DB868 (118 DPI). However, only 2/4 daily doses of melarsoprol were administered, after
which the monkey’s clinical condition deteriorated significantly, necessitating euthanasia.
In summary, a combined cure rate of 2/10 was achieved with oral DB868. Two monkeys
were not provisionally cured and six monkeys eventually relapsed. Of those that relapsed, 5/6
were successfully rescue-treated with melarsoprol; the final monkey had to be euthanized prior
to the start of rescue-treatment.
Infection- and Treatment-Induced Haematological Changes
In all DB829 and DB868 treatment groups, red blood cell (RBC) counts exhibited an infection-
induced decline that was most prominent at the last pre-treatment sampling point, 27 DPI
(Fig. 6). For the monkeys in the DB829 study (n = 6), the decline in RBC counts was significant
(p< 0.0001), from a baseline (0 DPI) mean (± SE) of 5.9 ± 0.3 to 4.7 ± 0.3 at 27 DPI. These
monkeys also had a significant decline in haematocrit (p< 0.0001), from a mean (± SE) of 48.8
(± 2.6)% at baseline (0 DPI) to 35.5 (± 1.8)% at 27 DPI, a 27.3% decrease. Similarly, monkeys
in the DB868 study (n = 10) experienced significant infection-related declines (p< 0.0001) in
both RBC counts and haematocrit. The mean corpuscular volume and mean corpuscular hae-
moglobin for all groups of monkeys also declined significantly (p< 0.05), consistent with pre-
vious findings in monkeys infected with the same T. b. rhodesiense KETRI 2537 isolate [13].
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Upon treatment with DB829 IM or DB868 orally, RBC counts recovered to baseline levels
within approximately 1–2 months (Fig. 6). The average RBC counts of all treatment groups re-
mained stable throughout the remainder of the study (Fig. 6), despite the occurrence of relapse
at various times for different monkeys treated with DB868.
Infection-related thrombocytopenia was observed between 7–27 DPI (Table 4). Within
one week post-LDD of DB868, platelet cell counts had recovered to baseline (pre-infection)
levels. Similarly, leukopenia was observed at 7 DPI (Table 4) and was largely due to declines in
lymphocyte and granulocyte numbers (Fig. 7A); monocyte numbers remained stable through-
out. However, unlike RBC and platelet counts, which remained low prior to therapeutic inter-
vention with DB829 or DB868, white blood cell (WBC) densities exhibited wide variability
Fig 6. Red blood cell density changes in infected vervet monkeys treated with experimental drugs.
Monkeys were infected with T. b. rhodesiense KETRI 2537 and upon confirmation of onset of second stage
HAT, treated with (A) DB829 or (B) DB868. DB829 was administered intramuscularly for either 5 consecutive
days (28–32 days post-infection) or 5 alternate (*) days (28, 30, 32, 34 and 36 days post-infection). DB868
was administered orally for 10 consecutive days (28–37 days post-infection). Symbols represent means
(A; n = 2) or means and standard error of the mean (B; n = 4).
doi:10.1371/journal.pntd.0003409.g006
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between individuals, rebounding in some monkeys while remaining low in others (Table 4;
Fig. 7A). Upon treatment with DB829 or DB868, meanWBC counts for all treatment groups
returned to baseline levels (Table 4). In individual monkeys, however, WBC counts continued
to fluctuate, especially in those monkeys that eventually relapsed (Fig. 7A and 7B). The highest
WBC peaks that occurred in the relapsed monkeys were observed approximately 1–4 days
post-LDD of melarsoprol (Fig. 7B). These peaks were largely the result of lymphocyte and
granulocyte increases (Fig. 7B).
Pharmacokinetics
Following IM injection of the active diamidine DB829 (Fig. 8), the median plasma Tmax of the
2.5and 5 mg/kg/day consecutive-day dose groups were similar (0.04 days or 1 h; Table 5). The
geometric mean Cmax and AUC for the 5 mg/kg/day group was 2.7-and 2.1-fold higher, respec-
tively, than that for the 2.5 mg/kg/day dose group (Table 5). The geometric mean (range) ter-
minal half-life (t½) for the consecutive-day dosing regimens was 38 (33–44) days. Geometric
mean Cmax and median Tmax for alternate-day dosing with 5 mg/kg/day were comparable to
those for consecutive-day dosing (Table 5). The AUC and the terminal half-life for the alter-
nate-day dosing regimen were 5- and 4-fold greater, respectively, than corresponding values
for the consecutive-day dosing regimen (Table 5).
Following oral administration of DB868, the prodrug was detected within 1 h post-LDD in
all monkeys, with geometric mean plasma concentrations (range) of 120 (100–150) nmol/L for
the 3 mg/kg/day group, 750 (420–1500) nmol/L for the 10 mg/kg/day group, and 810 (370–
1300) nmol/L for the 20 mg/kg/day group. Concentrations declined rapidly and were undetect-
able after 8 h in all monkeys, precluding accurate recovery of pharmacokinetic outcomes for
DB868. Oral DB868 was converted to the active drug DB829 in all the monkeys (Fig. 9). Medi-
an plasma Tmax for DB829 was 0.33 days (8 h) for the three treatment groups, ranging from
0.04–2.0 days (1–48 h; Table 6). Geometric mean Cmax (range) was 85 (60–110) nmol/L for the
3 mg/kg/day group, 270 (180–410) nmol/L for the 10 mg/kg/day group, and 530 (460–630)
nmol/L for the 20 mg/kg/day group (Table 6). Because rescue-treatment with melarsoprol
Table 4. Changes in blood platelet and white cell counts following infection of monkeys with T. b. rhodesiense and subsequent treatment within
tramuscular DB829 and oral DB868.
Drug Dose (mg/kg × d) DPI (DPT) 0 7 27 38 (1) 44 (7) 65 (28) 100 (63) 137 (100) 224 (180)
DB829 5 × 5a PLT 424 ± 60 112 ± 11 156 ± 42 464 ± 32 515 ± 39 419 ± 4.5 352 ± 44 367 ± 60 N/A
WBC 6.0 ± 0.4 3.4 ± 0.5 4.6 ± 0.2 7.8 ± 0.3 6.6 ± 0.5 7.3 ± 1.0 5.3 ± 1.1 4.5 ± 0.1 N/A
5 × 5b PLT 312 ± 31 96 ± 12 200 ± 2 328 ± 7.5 395 ± 26 378 ± 71 246 ± 26 327±25 250 ± 53
WBC 4.8 ± 0.5 3.3 ± 1.1 4.7 ± 0.6 4.8 ± 0.6 5.6 ± 0.5 6.5 ± 0.7 5.8 ± 0.8 6.3 ± 0.3 6.0 ± 0.3
2.5 × 5a PLT 285 ± 23 54 ± 20 115 ± 32 265 ± 17 332 ± 27 292 ± 5 242 ± 64 327 ± 27 389 ± 13
WBC 5.8 ± 2.1 3.9 ± 1.4 5.4 ± 1.3 6.8 ± 1.5 8.9 ± 3.4 8.1 ± 2.1 6.3 ± 1.0 6.0 ± 1.6 6.7 ± 1.9
DB868 20 × 10a PLT 323 ± 42 112 ± 15S 131 ± 32S 410 ±14 362±57 334±52 318± 31 285± 51 243±50
WBC 8.1± 1.5 3.5 ± 0.8S 4.3 ± 0.7S 7.4 ± 0.8 6.5± 0.6 5.9 ± 0.3S 6.9 ± 0.6 8.1 ± 0.6 9.7± 2.9
10 × 10a PLT 273 ± 76 75 ± 13 54 ± 4 292 ± 41 331 ± 90 307 ± 82 217 ± 32 451 ± 65 337 ± 19
WBC 5.7 ± 0.3 2.7 ± 0.2S 4.3 ± 0.6 8.9 ± 0.3 7.1 ± 0.8 6.9 ± 0.7 7.9 ± 1.7 6.2 ± 0.5 6.4 ± 0.6
3 × 10a PLT 355 ± 215 259 ± 186 126 ±33 472 ±248 N/A
WBC 5.7 ± 0.8 4.7 ± 0.6 6.4 ± 0.5 8.2 ± 0.6 N/A
Key: d, day;DPI, days post-infection; DPT, days post-treatment (post-last drug dose of DB829 or DB868); a, consecutive-day dosing; b, alternate-day
dosing; PLT, platelet counts;WBC, white blood cell counts; N/A, not applicable; S, p < 0.05 (repeated measures ANOVA with Fisher’s PLSD post hoc
test).
doi:10.1371/journal.pntd.0003409.t004
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started as early as 63 days post-LDD of DB868 due to relapse (monkeys 688M and 697F), only
the partial exposure (AUC0–63) of DB829 was evaluated for all DB868-treated monkeys. The
geometric mean AUC0–63 for the 10 mg/kg/day and 20 mg/kg/day groups were approximately
3- and 4-fold greater, respectively, than that recovered for the single monkey in the 3 mg/kg/
day group (Table 6). An accurate terminal elimination half-life was not recoverable for all
monkeys (Table 6), precluding dose-comparisons.
CSF active drug (DB829) concentrations were determined only for monkeys treated with
DB829IM; CSF concentrations were not quantifiable in monkeys treated with oral DB868.
Concentrations in the 2.5 mg/kg/day consecutive-day dose group were below the limit of quan-
tification (5 nmol/L). In the 5 mg/kg/day consecutive-day dose group, the geometric mean
DB829 concentration was 14 nmol/L at 1 h post-LDD; concentrations decreased to below the
Fig 7. White cell changes in the blood of three infectedmonkeys treated with the diamidine prodrug DB868.DB868 was administered orally at
20 mg/kg/day (689M), 10 mg/kg/day (688M), or 3 mg/kg/day (687M) for 10 days after infection with T. b. rhodesiense KETRI 2537 (28–37 days post-
infection). Confirmed relapses were rescue-treated with melarsoprol intravenously at 3.6 mg/kg/day for 4 consecutive days. White blood cell changes from
(A) -14 to 93 days and (B) 93 to 268 days post-infection. M, male; WBC, white blood cells; LY, lymphocytes; GR, granulocytes. Dashed arrows, last DB868
dose; bold arrows, last melarsoprol dose.
doi:10.1371/journal.pntd.0003409.g007
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Fig 8. Plasma concentration-time profiles following administration of the active diamidine DB829 to infected vervet monkeys.Monkeys confirmed to
have second stage HAT were administered DB829 intramuscularly, beginning at 28 days post-infection with T. b. rhodesiense KETRI 2537, at 5 mg/kg/day
for 5 consecutive days, 5 mg/kg/day for 5 alternate days or 2.5 mg/kg/day for 5 consecutive days. The inset graph shows the extended profile out to the end
of the study. * denotes the time (91 days post-last drug dose) that monkey 659 was euthanized due to non-drug related complications (pneumonia). F,
female; M, male.
doi:10.1371/journal.pntd.0003409.g008
Table 5. Pharmacokinetics of DB829 in vervet monkeys with second stage HAT after the 5th intramuscular dose.
Group 1 Group 2 Group 3
Outcome Units 569F 659M 668M 676F 546M 693F
Tmax day 0.04 0.04 0.04 0.04 0.04 0.04
Cmax nmol/L 12000 15000 16000 8900 4200 5900
AUClast
† nmol/L•day 12000 13000 97000 35000 7700 4500
AUC0-1 nmol/L•day 13000 15000 120000 40000 8300 5300
Cl/F L/day/kg 0.85 0.76 0.09 0.28 0.67 1.0
t½ day 34 44 130 180 33 42
Group 1 = 5 mg/kg × 5 consecutive days; Group 2 = 5 mg/kg × 5 alternating days; Group 3 = 2.5 mg/kg × 5 consecutive days; F, female; M, male; Tmax,
time to reach Cmax; Cmax, maximum concentration; AUClast, AUC from time 0 to the last measurable concentration; AUC(0-1), AUC from 0 to infinite time;
Cl/F, apparent clearance; t½, terminal half-life;
† = last measurable concentration varied between monkeys (112–490 days).
doi:10.1371/journal.pntd.0003409.t005
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limit of quantification by 28 days post-LDD. In the 5 mg/kg/day alternate-day dose group, the
geometric mean concentration was 7.3 nmol/L at 1 h post-LDD. A similar concentration of
DB829 was detected at 2 days post-LDD before decreasing below the limit of quantification.
Discussion
A variety of novel diamidines and corresponding prodrugs, notably the prodrugs pafuramidine
and DB844, have demonstrated high activity against African trypanosomes both in vitro and in
mouse models of first and second stage HAT [10, 11, 27]. Recently, it was demonstrated that
the prodrug DB868 was better tolerated than pafuramidine in rats [28]. Oral DB868 was dem-
onstrated further to be well tolerated and highly active in a vervet monkey model of first stage
HAT, supporting DB868 as a potential clinical candidate for first stage human disease [14]. In
the current study, the efficacy and pharmacokinetics of oral DB868 and its active diamidine,
IM DB829, were investigated in the vervet monkey model of second stage HAT.
Fig 9. Plasma concentration-time profiles of DB829 following administration of the diamidine prodrug DB868 to infected vervet monkeys.Monkeys
confirmed to have second stage HAT were administered DB868 orally, beginning at 28 days post-infection with T. b. rhodesiense KETRI 2537, at 20, 10 or 3
mg/kg/day for 10 consecutive days. The inset graph shows the extended profile out to the end of the study. * denotes the time that monkey 670 (1 day post-
last drug dose), monkey 687 (82 days post-last drug dose) and monkey 696 (130 days post-last drug dose) were euthanized due to clinical morbidity.
F, female; M, male.
doi:10.1371/journal.pntd.0003409.g009
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IM DB829 at all dose regimens tested cured all monkeys with second stage HAT, whereas
oral DB868 cured a combined 2/10 monkeys. These results indicate improved activity of IM
DB829 compared to oral DB868 and other previously evaluated oral prodrug analogues, in-
cluding pafuramidine, which cured 0/3 monkeys [12], and DB844, which cured 3/7 monkeys
[13]. The efficacy of IM DB829 also was superior to that of IM pentamidine, which showed a
moderate cure rate (2/3) in first stage disease [14] but was ineffective (0/3) when treatment ini-
tiation was delayed to 14 days post-infection with T. b. rhodesiense KETRI 2537 (unpublished
data, TRC-KARI). Another study evaluating the efficacy of diminazene aceturate and other ex-
perimental diamidines against second stage T. b. rhodesiense infections in monkeys reported a
low cure rate (2/8), with a majority of the monkeys relapsing and progressing to meningo-
encephalitis [18]. The current results indicate that, unlike other diamidines and diamidinepro-
drugs previously evaluated in this monkey model, DB829 potentially could be developed as
therapy for second stage HAT.
The geometric mean plasma Cmax of DB829 after IM administration of 5 and 2.5 mg/kg/day
was 25 and 10-times greater, respectively, than that after oral administration of DB868 at 20
mg/kg/day. These results could reflect presystemic loss of DB868, intermediate metabolites,
and/or DB829 after oral administration of DB868; however, additional studies are needed to
confirm this contention. Although the prodrug strategy improves delivery of dicationic drug
molecules through biologic membranes [29], making oral administration of these compounds
an attractive therapeutic option especially relevant for resource-poor HAT endemic regions
[13], our current findings indicate that parenteral administration may be preferred for the sec-
ond stage cases due to the superior systemic exposure of active compounds. The long half-life
for DB829 (33–180 days) given IM or orally as DB868 is consistent with the dicationic nature
of DB829. The observation that the AUC and terminal elimination half-life for the alternate-
day DB829 regimen were 5-times greater than those for the consecutive-day dosing regimens is
not easily explained. More studies are needed to verify, and explain, these results.
Evaluation of CSF from monkeys treated with IM DB829 at 5 mg/kg/day following either
dosing regimen suggested that DB829 penetrated the BBB, attaining peak geometric mean con-
centrations at 1 h post-LDD of approximately 14 nmol/L (consecutive-day dosing) or 7.3
nmol/L (alternate-day dosing). These concentrations were approximately 0.1% of
Table 6. Pharmacokinetics of DB829 Pharmacokinetics of DB829 in vervet monkeys with second stage HAT after the 10th oral dose of DB868.
Monkey Tmax (day) Cmax (nmol/L) AUC0–63 (nmol/L•day) t½ (day)
20 mg/kg × 10 days 573F 1 460 7700 48
679F 0.33 630 13000 NC‡
689M 0.17 500 4700 180
696M 0.17 530 5900 NC‡
10 mg/kg × 10 days 688M 0.04 410 2500 NC‡
690F 2.0 340 5100 120
695M NC* NC* NC* NC*
697F 0.33 210 NC† NC†
3 mg/kg × 10 days 670F 0.33 60 NC† NC†
687M 0.33 110 1800 NC‡
Tmax, time to reach Cmax; Cmax, maximum concentration; AUC0–63, AUC from 0 to 63 days; t½, terminal half-life; F, female; M, male; NC, not calculable;* =
data was too sparse to determine the Tmax, Cmax, AUC0–63, and t½ with confidence;
† = data was too sparse to determine the AUC0–63, and t½ with confidence;
‡ = data was insufficient in the terminal phase to determine the t½ with confidence.
doi:10.1371/journal.pntd.0003409.t006
Chemotherapy of Second Stage HAT with Novel Diamidines DB829 and DB868
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003409 February 5, 2015 18 / 22
corresponding total (bound + unbound) plasma concentrations at the 1 h post-LDD time
point. All the IM treated monkeys were cured, implying that these concentrations attained the
minimum threshold required for efficacy. Indeed, these concentrations compared favourably
with the in vitro IC50 for DB829 (14 nmol/L) determined for T. b. rhodesiense STIB900 [11]. In
addition, DB829 CSF concentrations were maintained above 5 nmol/L for 2–28 days post-
LDD. The persistence of DB829 in CSF may have enabled trypanosomes to accumulate poten-
tially lethal drug concentrations as found previously following pharmacological studies of
DB844 in monkeys [13]; in vitro accumulation and distribution studies of DB75 and DB820 in
African trypanosomes led to similar conclusions [30]. The success of DB829 in curing second
stage infection, despite seemingly low CSF concentrations, is consistent with melarsoprol and
eflornithine, both of which have a historically high success rate against second stage HAT [3]
despite attaining comparably low CSF:plasma ratios [31, 32].
Drug concentrations were not quantifiable in CSF of monkeys treated with the generally un-
successful oral DB868 treatment regimens, suggesting that DB829 either did not penetrate the
BBB or that CSF/CNS concentrations attained were insufficient to cure. The relapsed monkeys
manifested a more advanced second stage disease compared to primary infections in the same
individuals, substantiating the important role of the CNS as a reservoir of drug-evading, re-
lapse-causing trypanosomes [13]. In addition, parasitaemia in the relapsed monkeys did not
reach the peak levels observed in primary parasitaemia (Fig. 5) and was more comparable to
the pattern observed in T. b. gambiense infections in vervet monkeys [33] (unpublished data,
TRC-KARI); human T. b. gambiense infections, which comprise more than 95% of HAT, are
similarly characterised by very low parasitaemias [3, 34, 35]. Our study did not elucidate the
factors responsible for the generally lower parasite loads detected in the blood of relapse as
compared to primary infections in the same monkeys. However, it has been reported previous-
ly that blood parasite loads in T. brucei. spp infections are a product of density-dependent para-
site differentiation to the non-replicating short stumpy forms, as well as the killing of parasites
by the host’s immune system [36]. Our results are suggestive of a predominance of short
stumpy forms and/or a more efficient killing of successive trypanosome variant antigenic types
by the immune system in the chronic relapse infections in monkeys.
Time to relapse data for monkeys treated with DB868 at 20 mg/kg/day, a median 133
(range, 77–161) days post-LDD, was a positive indicator that the protracted timelines observed
before declaration of cure in preclinical studies in the monkey model [12, 13] and in routine
management of HAT patients [3] are not without justification. Primary efficacy endpoint as-
sessments at 30 or 100 days post-LDD have been proposed to improve the approval times for
compounds in development for second stage HAT. In our study, a primary efficacy endpoint
of 30 days post-LDD would have had little or no value in predicting the final efficacy outcome.
However, a primary efficacy endpoint of 100 days post-LDD would have predicted correctly
the efficacy outcome for the oral DB868 10 mg/kg/day group but not for the 20 mg/kg/day
group since 2/3 relapses in this group were diagnosed as relapses after 100 days post-LDD of
DB868. Nevertheless, a review of larger data sets of monkeys treated with different experimen-
tal diamidines in our laboratory revealed that a primary endpoint at 100 days post-LDD would
have facilitated detection of 20/25 (80%) animals that eventually relapsed (unpublished data,
TRC-KARI), indicating that 100 days may be a useful endpoint for go-no go decisions during
preclinical drug trials.
Haematology changes attributable to trypanosome infection and subsequent treatment with
diamidines were generally consistent with previous observations in this model [12, 13, 37].
However, the current study focused more on total and differential WBC counts in blood. Al-
though WBC changes exhibited wide variations, the finding that WBC remained elevated in
monkeys that eventually relapsed, suggests that it could be investigated further as a potential
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surrogate marker for cure assessment in this model. Other potential surrogate tests for cure as-
sessment include WBC counts in CSF [38], serum/plasma trypanosome antigen levels as deter-
mined using TrypTECTT CIAT [23], HAT ELISA [39], and a variety of DNA-based
polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP) tech-
niques [40, 41]. However, all these surrogate tests require validation to be used as biomarkers
of cure/relapse in drug trials. Other significant haematological changes observed in our current
study included elevation in WBC counts, especially lymphocytes and granulocytes, during and
immediately post-trypanocidal therapy (Fig. 7A and 7B). The WBC changes were most pro-
nounced post-treatment with melarsoprol and likely reflected rapid destruction of trypano-
somes, the release of high amounts of trypanosome antigens (antigenaemia) and associated
stimulatory effects on the host’s immune system; however, the significance of these WBC
changes needs to be verified in a future study. Importantly, the elevated leukocyte numbers re-
turned to baseline within approximately four days post-LDD of curative melarsoprol therapy
(Fig. 7B).
In summary, the current study demonstrated that 10-day dose regimens of the oral diami-
dine prodrug DB868 did not yield satisfactory efficacy in the monkey model of second stage
HAT, similar to the oral prodrug analogue DB844 [13]. Further studies are needed to deter-
mine whether alternate regimens in which the prodrug is administered at higher daily doses
for shorter durations could improve efficacy without compromising safety. A low dose
(2.5 mg/kg/day) of the active diamidine DB829, administered IM for 5 consecutive days, was
identified as a promising new treatment that could enter the development pipeline for second
stage HAT. It has previously been reported that DB829 was effective against multiple
T. b. rhodesiense and T. b. gambiense isolates in vitro and in murine models of HAT [42, 43],
which when taken together with the current results, indicates that DB829 should be considered
a potential clinical candidate for both forms of HAT.
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